.jpg)
.png)
Introduction:
Article By:
Associate Research Scientist
Director of Nutrition
Irving Institute for Clinical and Translational Research
Columbia University
New York, NY
Diplomate, Accreditation Council for Clinical Lipidology
Changed lifestyles and diet have been associated with the current obesity epidemic. Pharmacologic interventions date back to the Greco-Roman era when laxatives coupled with exercise and other modalities to facilitate weight loss were prescribed or used. Many still remember the use of the following medications: thyroid hormone, amphetamines, digitalis, diuretics and dinitrophenol. These were early 20th century options. Phentermine was approved in 1959 by the U.S.
Article By:
Clinical Pharmacy Coordinator, VA Western
New York Healthcare System
Buffalo, NY
Diplomate, Accreditation Council for Clinical Lipidology
Let’s not confuse health care cost and health. Health care cost is the amount of money spent predominantly for the diagnosis and treatment of people with an acute illness or a chronic disease. The cost is related to the number of encounters and the cost per encounter. It is estimated that one third of health care costs are related to unnecessary care.
Article By:
Medical Director of Cardiovascular Prevention and Employee Wellness
Christiana Care Health System
Chairman, Million Hearts Initiative Delaware
Newark, DE
Diplomate, American Board of Clinical Lipidology
It is with great pride and excitement that I compose this chapter message. Conveniently, this issue of Lipid Spin falls midway through my year as President of NELA, and therefore provides a perfect opportunity to update you on where we are, and where we are going.
Article By:
President, Northeast Lipid Association
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for Prevention
of Cardiovascular Disease
Director Bellevue Hospital Lipid Clinic
New York, NY
Diplomate, American Board of Clinical Lipidology
The National Lipid Association along with a panel of outside experts from various disciplines convened for a workshop in late July to examine how health information technology (HIT) can be used, to effectively improve LDL-C goal attainment. The workshop committee of experts included participants from academic medical centers, health care policy organizations, large health care systems, as well as members from the HIT and pharmaceutical industries.
The National Lipid Association has endorsed the following Guidelines:
Patient LH, a 39-year-old white male came to me for evaluation as he was concerned about his risk for coronary heart disease (CHD). His father had coronary artery disease at age 46. He had 99% blockage of his right coronary artery and subsequent stent placement. While not first degree relatives, he also has several aunts, uncles, and cousins with early coronary heart disease (defined as women prior to age 55 and women prior to age 65).
Article By:
Director, Center for Cardiovascular Disease Prevention
Director, Cardiology Section, Center for Comprehensive Care (HIV) Clinic
Attending Cadiologist
St. Luke’s-Roosevelt Hospital New York, NY
Assistant Professor of Clinical Medicine and Epidemiology
Columbia University College of Physicians and Surgeons
New York, New York
The Foundation of the National Lipid Association has accomplished much since its creation four years ago, but we want to continue to grow. Over the past year, I have been engaged in conversations with leadership, members, staff and patients about the future of our charitable organization. As we look ahead to the way the Foundation will define its agenda in the coming years, several themes consistently emerge.
Article By:
President, Foundation of the National Lipid Association
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, MO
Diplomate, American Board of Clinical Lipidology
By Jennifer J Brown, PhD, Everyday Health Staff Writer
Matt Ito, PharmD, is the president of the National Lipid Association for a very good reason. He has inherited a dangerously high cholesterol condition called familial hypercholesterolemia, or FH, which affects more than 600,000 people in the United States.